Navigation Links
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Date:12/8/2008

e first infusion and 2,000 mg of ofatumumab at each subsequent infusion. Disease status is assessed every four weeks until week 28 and then every three months until disease progression or month 24.

The interim analysis included 138 treated patients (DR, n=59; BFR, n=79). Patient recruitment is ongoing and a final analysis will be conducted on the full study population, expected to be 100 patients in each group.

The primary endpoint of the study is objective response over a 24 week period from start of treatment as assessed according to the National Cancer Institute Working Group guidelines by an Independent endpoint Review Committee (IRC). Secondary endpoints included duration of response, progression free survival, time to next CLL therapy, overall survival and adverse events.

About ofatumumab

Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing-remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for any indication in any country.

About CLL

CLL is the most common leukemia and one of the most common malignant lymphoid diseases.(2) Globally, leukemia accounts for some 300,000 new cases each year (2.8 percent of all new cancer cases) and 222,000 deaths.(7)

Conference Call

Genmab will hold a conference call to discuss these results tomorrow, December 9, 2008 at:

3:00 pm CEST

2:00 pm BST

9:00 am EST

The conference call will be held in English.

The dial in numbers are as follows:

+1 877 723 9518 (in the US) and ask for the Genmab conference call

+1 719 325 4812 (outside the US) and ask for the Genmab conference call <
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- VWR (NASDAQ: VWR ), a leading, ... redesign of its global website, www.vwr.com , to improve ... new site, guests will enjoy enhanced content on a modern ... country site now includes: , a simplified ... , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... India, Oct. 19 Cardiac Science Corporation (Nasdaq: ... NSE: OPTOCIRCUI] today announced they have entered into a definitive ... all of the outstanding shares of Cardiac Science common stock ... 10% premium to the closing price of Cardiac Science common ...
... 18 Althea Technologies, Inc., a leading provider ... parenteral drug products, announced today that it has ... high-speed syringe filling line.  This line is located ... in San Diego. The expanded capacity complements existing ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2
(Date:8/3/2015)... , ... August 03, 2015 , ... ... ALS and amputation , AUGUST 3, 2015 – Since winning a South by ... 2015, Not Impossible – an organization whose mission is to develop technology for ...
(Date:8/3/2015)... ... 2015 , ... The art of preparing and cooking food comes naturally to ... young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she ... My Persian Kitchen with the world. , Since Americans tend to be undereducated about ...
(Date:8/3/2015)... ... 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing ... Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien ... Company’s presentation may be accessed via the investor relations section of the Company’s website. ...
(Date:8/3/2015)... OR (PRWEB) , ... August 03, 2015 , ... ... California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its ... California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi Lava ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... characterization of renal transplant patients being weaned ... ... Data developed by Cylex in,conjunction with the University of Pittsburgh ... Canada, suggest,that cell-mediated immunity and anti-HLA antibody assays may be independent,measures ...
... COLUMBUS, Ohio Mothers play an important role in determining ... infants, according to new research. , A study of 97 ... care of their infants when they received active encouragement from ... important even after taking into account fathers and mothers views ...
... Three new studies published in the June 2008 ... on what role gender plays in the prognosis of ... the success rates of hearing aid implants in the ... wide variety of critical research being undertaken every day ...
... finds , , SATURDAY, May 31 (HealthDay News) -- ... survival in women with advanced breast cancer, new ... adding Avastin (bevacizumab) to the chemotherapy drug Taxol ... doubled progression-free survival. , Avastin is already approved ...
... Anti-angiogenesis drug prolonged progression-free survival, study finds , , ... drug Avastin to chemotherapy lengthened progression-free survival in ... , Previous studies have found that adding Avastin ... women with advanced breast cancer actually doubled progression-free ...
... Two Phase II studies demonstrated potential for pazopanib as a single,agent treatment ... -- In patients with stage I-III non-small cell lung cancer, ... monotherapy experienced a reduction in tumor volume ... an overall response rate of 35 percent. ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Mom's behavior key to dad's involvement in child care 2Health News:Mom's behavior key to dad's involvement in child care 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8
... Test is an immunochromatography based ... is designed for qualitative determination ... The presence of myoglobin in,serum ... higher can be detected in ...
... test kit is an immunochromatographic in vitro ... immunoglobulin E in human serum or plasma. ... with allergic pathologies. It may also be ... Rapid detection of IgE using InstaTest IgE ...
... physiological monitor offers a comprehensive array of ... for pediatric and neonate patients, to magnetic ... Veris is the first MR monitor designed ... and neonate patient monitoring. The new monitor ...
... AFP is an immunochromatographic in vitro assay ... in human serum. AFP is a protein ... 74,000 D. Its normal concentration in serum ... associated with hepatoma and ovarian, testicular and ...
Medicine Products: